[
{
	"page":"ENAS5268_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-‍Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Central venous access in oncology: ESMO Clinical Practice Guidelines Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D and Cardoso F, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v152–68 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v152.full.pdf+html Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Peterson DE, Boers-‍‍Doets CB, Bensadoun RJ and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26 (Suppl 5):v139–51 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍26/‍suppl_5/v139.full.pdf+html Prevention of chemotherapy-‍‍ and radiotherapy-‍‍induced nausea and vomiting and of nausea and vomiting in advanced cancer patients: 2016 MASCC and ESMO guideline update Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-‍‍Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D and van der Wetering M, on behalf of the participants of the MASCC-‍‍ESMO Consensus Conference Ann Oncol 2016; 27 (Suppl 5): v119–33 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v119.full.pdf+html Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Mandalà M, Falanga A and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2011;22(Suppl 6):vi85–92 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍22/‍suppl_6/vi85.full.pdf+html Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii155–66 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii155.full.pdf+html Management of chemotherapy extravasation: ESMO-‍EONS Clinical Practice Guidelines Pérez Fidalgo JA, García Fabregat L, Cervantes A, Marguiles A, Vidall C and Roila F, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012;23(Suppl 7):vii167–73 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍23/‍suppl_7/vii167.full.pdf+html Management of febrile neutropaenia: ESMO Clinical Practice Guidelines Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M and Herrstedt J, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v111–8 http:/‍/‍annonc.oxfordjournals.org/‍content/‍‍27/‍suppl_5/v111.full.pdf+html Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines Roselló S, Blasco I, García Fabregat L, Cervantes A and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv100–18 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv100/18528215/​mdx216.pdf Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv119–42 https://​academic.oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv119/​3958159/​mdx225.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPGs) and consensus statements on various aspects of supportive care for your patients. Key content includes central venous access in oncology; prevention of chemotherapy-‍‍ and radiotherapy induced nausea and vomiting; and management of febrile neutropenia, mucositis, venous thromboembolism, extravasation associated with the administration of chemotherapeutic agents and of the cardiotoxic effects of chemotherapy and radiotherapy. The ESMO CPG and consensus statements covered in this booklet are intended to provide you with a set of recommendations for the best standards of supportive care, using evidence-‍‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on supportive care in cancer. Please visit http://www.esmo.org or http://oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5268_2.1.0.0",
	"text":"2.0.0.0 PREVENTION OF CINV 2.1.0.0 Levels of emetogenicity A four-‍level classification of intravenous (IV) chemotherapy agents has been accepted by registration authorities and groups producing recommendations on antiemetics: high (emetic risk > 90%), moderate (30–90%), low (10–30%) and minimal (< 10%) The broad range of expected emesis in the moderate level is a challenge to the provision of a single recommendation for antiemetic treatment appropriate for the entire moderate category A systematic search of agents introduced since the 2010 guidelines allowed 41 of 42 new antineoplastic agents to be classified in alphabetical order and according to emetogenic risk in adults, as shown in the table below EMETOGENIC POTENTIAL OF SINGLE INTRAVENOUS ANTINEOPLASTIC AGENTS   IV CHEMOTHERAPY ORAL CHEMOTHERAPY* HIGH Anthracycline/‍cyclophosphamide combination† Carmustine Cisplatin Cyclophosphamide ≥ 1500 mg/m2 Dacarbazine Mechlorethamine Streptozocin Hexamethylmelamine Procarbazine MODERATE Alemtuzumab Azacitidine Bendamustine Carboplatin Clofarabine Cyclophosphamide < 1500 mg/m2 Cytarabine > 1000 mg/m2 Daunorubicin Doxorubicin Epirubicin Idarubicin Ifosfamide Irinotecan Oxaliplatin Romidepsin Temozolomide‡ Thiotepa§ Trabectedin Bosutinib Ceritinib Crizotinib Cyclophosphamide Imatinib Temozolomide Vinorelbine LOW Aflibercept Belinostat Blinatumomab Bortezomib Brentuximab Cabazitaxel Carfilzomib Catumaxumab Cetuximab Cytarabine ≤ 1000 mg/m2 Docetaxel Eribulin Etoposide 5-‍Fluorouracil Gemcitabine Ipilimumab Ixabepilone Methotrexate Mitomycin Mitoxantrone Nab-‍paclitaxel Paclitaxel Panitumumab Pemetrexed Pegylated liposomal doxorubicin Pertuzumab Temsirolimus Topotecan Trastuzumab-‍emtansine Vinflunine Afatinib Axatinib Capecitabine Dabrafenib Dasatinib Everolimus Etoposide Fludarabine Ibrutinib Idelalisib Lapatinib Lenalidomide Olaparib Nilotinib Pazopanib Ponatinib Regorafenib Sunitinib Tegafur Uracil Thalidomide Vandetanib Vorinostat MINIMAL Bevacizumab Bleomycin Busulfan 2-‍Chlorodeoxyadenosine Cladribine Fludarabine Nivolumab Ofatumumab Pembrolizumab Pixantrone Pralatrexate Rituximab Trastuzumab Vinblastine Vincristine Vinorelbine Chlorambucil Erlotinib Gefitinib Hydroxyurea Melphalan Methotrexate L-‍phenylalanine mustard Pomalidomide Ruxolitinib Sorafenib 6-‍Thioguanine Vemurafenib Vismodegib *Classified emetic potential of oral agents based upon a full course of therapy and not a single dose †The combination of an anthracycline and cyclophosphamide in patients with breast cancer should be considered highly emetogenic ‡No direct evidence found for temozolomide IV; as all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide §Classification refers to individual evidence from paediatric trials IV, intravenous The following new emetogenic agents were identified since the previous guidelines Highly emetogenic agents: none, although the combined anthracycline/ cyclophosphamide (AC) regimen for breast cancer is recommended for reclassification as a special case within this category, because delayed-‍phase treatment is different from cisplatin regimens Moderately emetogenic agents: seven (IV: temozolomide, trabectedin, romidepsin, thiotepa; Oral: bosutinib, crizotinib, ceritinib) Low emetogenic potential: 26 (IV: aflibercept, belinostat, blinatumomab, brentuximab, cabazitaxel, carfilzomib, eribulin, ipilimumab, nab-‍paclitaxel, pegylated liposomal doxorubicin, pertuzumab, trastuzumab-emtansine, vinflunine; Oral: afatinib, axatinib, dabrafenib, dasatinib, ibrutinib, idelalisib, nilotinib, olaparib, pazopanib, ponatinib, regorafenib, vandetanib, vorinostat) Minimally emetogenic: eight (IV: nivolumab, ofatumumab, pembrolizumab, pixantrone; Oral: pomalidomide, ruxolitinib, vemurafenib, vismodegib)"
},
{
	"page":"ENAS5268_2.2.1.0",
	"text":"2.2.0.0. Prevention by highly emetogenic ChT 2.2.1.0 Overview The 2010 guideline recommended a three-‍drug regimen including single doses of a 5-‍hydroxytryptamine [HT]3 receptor antagonist (RA), dexamethasone and aprepitant given before chemotherapy to prevent acute nausea and vomiting following chemotherapy of high emetic risk and dexamethasone plus aprepitant or aprepitant alone to prevent delayed nausea and vomiting in cisplatin-‍treated and AC-‍treated patients, respectively. Since then, new treatments have become available The neurokinin (NK)1 RAs, netupitant and rolapitant, have been approved by the United States Food and Drug Administration (FDA, netupitant as NEPA combined with palonosetron and rolapitant) and the European Medicines Agency (EMA, netupitant as NEPA combined with palonosetron) An IV formulation of aprepitant, fosaprepitant"
},
{
	"page":"ENAS5268_2.2.2.0",
	"text":"2.2.2.0 Cisplatin-‍treated patients The addition of an NK1 RA led to statistically and clinically significant improvements in response to anti-‍emetic treatment on day 1, days 2–5 and days 1–5 Foseprepitant (150 mg single dose) was as effective as the 3-day oral regimen of aprepitant The combination of netupitant and palonosetron was superior to palonosetron alone The addition of rolapitant significantly improved the effect of granisetron plus dexamethasone compared with placebo Therefore, for the prevention of non-‍AC highly emetogenic chemotherapy, a three-‍drug regimen including single doses of a 5-HT3 RA, dexamethasone, and an NK1 RA (aprepitant, fosaprepitant, netupitant or rolapitant), given before chemotherapy is recommended, with dexamethasone on days 2 to 4 to prevent delayed nausea and vomiting In patients receiving non-‍AC highly emetogenic chemotherapy treated with a combination of an NK1 RA, a 5-HT3 RA, and dexamethasone to prevent acute nausea and vomiting, dexamethasone on days 2 to 4 is suggested to prevent delayed nausea and vomiting For delayed nausea and vomiting, dexamethasone plus aprepitant or metoclopramide should be used in patients receiving aprepitant on day 1"
},
{
	"page":"ENAS5268_2.2.3.0",
	"text":"2.2.3.0 AC-‍treated female pts. with breast cancer Addition of netupitant to dexamethasone and palonosetron significantly increased the complete response on day 1 and days 1–5 and led to significantly fewer patients reporting an impact of nausea and vomiting on daily living, compared with palonosetron plus dexamethasone Addition of rolapitant to granisetron and dexamethasone significantly improved complete response on days 1–5 and 2–5 compared with granisetron and dexamethasone The improvement in the delayed and overall phases is clinically relevant because of the potential positive impact on the complete response rate in subsequent chemotherapy cycles Therefore, in women with breast cancer receiving AC chemotherapy, a three-‍drug regimen including single doses of a 5-HT3 RA, dexamethasone and an NK1 RA (aprepitant, fosaprepitant, netupitant or rolapitant), given before chemotherapy is recommended In women with breast cancer treated with a combination of a 5-HT3 RA, dexamethasone and an NK1 RA to prevent acute nausea and vomiting, aprepitant or dexamethasone should be used on days 2 and 3 but not if fosaprepitant, netupitant or rolapitant has been used in day 1 The use of steroids in the delayed phase tends to be reduced because of the side effects If an NK1 receptor antagonist is not available for the prophylaxis of nausea and vomiting induced by AC chemotherapy, palonosetron is the preferred 5-HT3 RA"
},
{
	"page":"ENAS5268_2.2.4.0",
	"text":"2.2.4.0 Are there differences between the NK 1 RAs? Aprepitant and netupitant are cytochrome P450 (CYP) 3A4 inhibitors and so significantly increase the exposure to oral dexamethasone, hence reduction of oral dexamethasone doses is recommended during co-‍administration (from 20 mg to 12 mg) Rolapitant is not an inhibitor or inducer of CYP3A4 but is a moderate inhibitor of CYP2D6 As there are no studies comparing the three NK1 RAs in terms of differences in efficacy and toxicity, choice may be dependent on convenience and cost"
},
{
	"page":"ENAS5268_2.2.5.0",
	"text":"2.2.5.0 Other highly emetogenic ChT These agents include mechlorethamine, streptozocin, cyclophosphamide > 1500 mg/m2, carmustine and dacarbazine Adding an NK1 RA to the combination of a 5-HT3 RA and dexamethasone for all non-‍cisplatin and non-‍AC highly emetogenic chemotherapy is recommended, although randomised studies have not been conducted"
},
{
	"page":"ENAS5268_2.3.1.0",
	"text":"2.3.0.0. Dose, schedule, route & safety of antiemetics 2.3.1.0 Overview Suggested doses, schedules and routes of administration of the 5-HT3 RAs, the NK1 RAs and dexamethasone are shown in the tables here (5-HT3 RAs, NK1 RAs and dexamethasone) Electrocardiographic changes, particularly QTc prolongation, are a class effect of 5-HT3 RAs, with palonosetron having the lowest risk IV dolasetron and IV ondansetron (32 mg) were withdrawn due to cardiac adverse events A transdermal formulation of granisetron was non-‍inferior to 3–5 days of daily oral granisetron and a patch providing 3.1 mg granisetron/‍24 hours for up to 7 days is available Non-‍inferiority of oral palonosetron 0.5 mg vs IV 0.25 mg has been confirmed with cisplatin-‍based chemotherapy or moderate emetogenic chemotherapy The 5-day binding of a single 165 mg oral dose of aprepitant was as high as that of a single 150 mg IV dose of fosaprepitant in healthy volunteers and this dose has received EMA (but not FDA) approval, although no clinical studies have been conducted Due to the risk of neurological effects, the EMA recommends that metoclopramide should not be used in children below 1 year of age and that the maximum dose for adults should be 30 mg/‍day (e.g. 10 mg x 3 orally) for no more than 5 days The authors of this guideline believe that 10 mg of metoclopramide is not superior to placebo in the effect against chemotherapy-‍induced nausea and vomiting and that higher doses are tolerable, when given for 2–3 days"
},
{
	"page":"ENAS5268_2.3.2.0",
	"text":"2.3.2.0 Doses of (5-HT)3 receptor antagonists AGENT ROUTE ANTIEMETICS Ondansetron IV 8 mg or 0.15 mg/Kg Oral 16 mg* Granistron IV 1 mg or 0.01 mg/Kg Oral 2 mg (or 1mg†) Dolasetron Oral 100 mg Tropisetron IV 5 mg Oral 5 mg Palonosetron IV 0.25 mg Oral 0.5 mg *Randomised studies have tested the 8 mg twice daily schedule †The 1 mg dose was preferred by some panellists 5-HT, 5-hydroxytriptamine; IV, intravenous"
},
{
	"page":"ENAS5268_2.3.3.0",
	"text":"2.3.3.0 Doses of corticosteroids DEXAMETHASONE DOSE AND SCHEDULE High risk Acute emesis 20 mg once (12 mg when used with (fos)aprepitant or netupitant)† Delayed emesis 8 mg bid for 3–4 days (8 mg once daily when used with (fos)aprepitant or netupitant) Moderate risk Acute emesis 8 mg once Delayed emesis 8 mg daily for 2–3 days (many panellists give the dose as 4 mg bid) Low risk Acute emesis 4–8 mg once *While corticosteroids other than dexamethasone are effective antiemetics, the dose and schedule of dexamethasone coupled with its wide availability in various dose forms established it as the guideline agent of choice †The 12 mg dose of dexamethasone is the only one tested with (fos)aprepitant/netupitant in large, randomised trials bid, twice daily"
},
{
	"page":"ENAS5268_2.3.4.0",
	"text":"2.3.4.0 Doses of NK1 receptor antagonists NK1 RECEPTOR ANTAGONIST DOSE AND SCHEDULE Aprepitant* and fosaprepitant - Acute emesis Aprepitant: 125 mg once on the day of chemotherapy* OR Fosaprepitant: 150 mg IV, once on the day of chemotherapy Aprepitant* and fosaprepitant - Delayed emesis Aprepitant 80 mg orally, once daily for the 2 days after chemotherapy; or none if fosaprepitant is used Rolapitant 180 mg orally once on the day of chemotherapy Netupitant 300 mg netupitant/0.5 mg palonosetron orally once on the day of chemotherapy *Aprepitant 165 mg as a single dose before chemotherapy (and none days 2–3) is registered by the EMA and other authorities, but no randomised clinical trials have tested this dose schedule EMA, European Medicines Agency; IV, intravenous; NK, neurokinin"
},
{
	"page":"ENAS5268_2.3.5.0",
	"text":"2.3.5.0 Olanzapine Olanzapine is an approved antipsychotic drug that blocks multiple neurotransmitters in the central nervous system: dopamine D1, D2, D3 receptors, serotonin 5-HT2a, 5-HT2c, 5-HT3 and 5-HT6 receptors, α1 adrenergic receptors, muscarinic receptors and histamine H1 receptors High complete response rates and high protection rates against nausea in patients receiving cisplatin-‍based or AC chemotherapy have been reported for olanzapine combined with a three-‍drug combination of a 5-HT3 RA, dexamethasone and the NK1 RA aprepitant Olanzapine appears to be superior to (fos)aprepitant in the prophylaxis of delayed nausea and equal to (fos)aprepitant in the prevention of acute symptoms Combination with a 5-HT3 RA plus dexamethasone can be considered, particularly when nausea is an issue, but patient sedation may be a concern with the 10 mg dose"
},
{
	"page":"ENAS5268_2.4.1.0",
	"text":"2.4.0.0 Prevention of MEC 2.4.1.0 Overview Previous Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) guidelines recommended palonosetron plus dexamethasone for the prophylaxis of acute nausea and vomiting For moderately emetogenic chemotherapy (MEC) associated with a significant incidence of delayed nausea and vomiting, antiemetic prophylaxis, preferably with multiday oral dexamethasone, for delayed emesis was recommended The prophylaxis of MEC-‍induced acute nausea and vomiting For the prevention of acute emesis in MEC-‍treated patients, a 5-HT3 RA plus dexamethasone is recommended Studies evaluating palonosetron versus other 5-HT3 RAs have almost exclusively been carried out in patients receiving cisplatin or breast cancer patients receiving AC An advantage for palonosetron compared with other 5-HT3 RAs, when both are combined with dexamethasone, has not been conclusively demonstrated The prophylaxis of MEC-‍induced delayed nausea and vomiting Previous data have demonstrated that some but not all patients may have reduced nausea or vomiting with the addition of dexamethasone beyond 24 hours No new data have emerged that allow the identification of patients at sufficiently high risk of delayed emesis to warrant prophylaxis Some new data are available for carboplatin and will be reviewed here For MEC agents other than carboplatin (see below), it can be concluded that in patients receiving MEC with a known potential for delayed emesis (e.g. oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered No routine prophylaxis for delayed emesis can be recommended for all other patients receiving MEC Which MEC should receive prophylaxis including an NK1 RA? Addition of an NK1 RA significantly improved antiemetic prophylaxis with 5-HT3 RA in MEC-‍treated patients Efficacy was demonstrated against AC and non-‍AC chemotherapy Not all MEC-‍treated patients have a sufficiently high risk of emesis to warrant prophylactic therapy including an NK1 RA from cycle 1 Addition of fosaprepitant (150 mg IV) to ondansetron plus dexamethasone significantly increased the complete response on days 1–5 and 2–5 compared with ondansetron plus dexamethasone in patients receiving non-‍AC MEC There was no difference between treatments in complete response on day 1"
},
{
	"page":"ENAS5268_2.4.2.0",
	"text":"2.4.2.0 Carboplatin In carboplatin-‍treated patients adding an NK1 RA to a 5-HT3 RA and dexamethasone increased the complete response by approximately 10–15% In a group of patients (the majority with gynaecological cancer) addition of aprepitant to granisetron plus dexamethasone increased the complete response rates on days 1–5, 1 and 2–5, but not significantly Adding aprepitant to 5-HT3 RA plus dexamethasone in patients scheduled to receive paclitaxel plus carboplatin for gynaecological cancers significantly increased the rate of complete response, no vomiting and no significant nausea Adding aprepitant to 5-HT3 RA plus dexamethasone in patients receiving carboplatin-‍based first-‍line chemotherapy for non-‍small cell lung cancer increased the complete response rate on days 1–5, but not significantly In conclusion, a combination of an NK1 RA, dexamethasone and a 5-HT3 RA is recommended to prevent carboplatin-‍induced acute nausea and vomiting Where fosaprepitant, netupitant or rolapitant is given on day 1, no antiemetic prophylaxis for delayed emesis is required Where aprepitant is given on day 1, aprepitant on days 2 and 3 is recommended"
},
{
	"page":"ENAS5268_2.4.3.0",
	"text":"2.4.3.0 Oxaliplatin Two large randomised trials came to conflicting conclusions about the role of NK1 RA for oxaliplatin-‍based chemotherapy-‍associated nausea and vomiting The addition of casopitant to ondansetron and dexamethasone did not significantly reduce vomiting compared with placebo and the low vomiting rate in both arms may have reflected ondansetron use The addition of aprepitant to dexamethasone and a 5-HT3 RA significantly increased the incidence of no vomiting overall and in the delayed phase In view of the discordant results, no recommendation can be made about combining an NK1 RA with dexamethasone and a 5-HT3 RA to for the prophylaxis of oxaliplatin-‍induced emesis"
},
{
	"page":"ENAS5268_2.5.0.0",
	"text":"2.5.0.0 Prev. by multiple-‍day cisplatin ChT Only a few studies have been carried out with multi-‍day chemotherapy studies including drugs such as dactinomycin, dacarbazine, ifosfamide and cisplatin In patients with germ cell tumours, the IV combination of a 5-HT3 RA plus dexamethasone Induced 55–83% complete protection from vomiting during the 3–5 days of cisplatin administration and was superior to IV high-‍dose metoclopramide plus dexamethasone, alizapride plus dexamethasone and to a 5-HT3 RA alone Markedly reduced the development of nausea and vomiting during the first 3 days of chemotherapy Addition of aprepitant to 5-HT3 RA plus dexamethasone significantly improved response rate compared with placebo, was preferred by patients and was not associated with increased toxicity The optimal dose and schedule of aprepitant, 5-HT3 RA as well as of dexamethasone remains to be identified Therefore, a 5-HT3 RA plus dexamethasone plus aprepitant is recommended for the prevention of acute nausea and vomiting and dexamethasone for delayed nausea and vomiting in patients receiving multiple-‍day cisplatin for metastatic germ cell tumours"
},
{
	"page":"ENAS5268_2.6.0.0",
	"text":"2.6.0.0 Prev. by ChT with low & min. emetogenic pot. Many newer targeted therapies have low or minimal emetogenic potential No guidelines recommend routine antiemetic prophylaxis against delayed emesis for low emetogenic chemotherapy, although delayed emesis can be problematic with such chemotherapy In conclusion, a single antiemetic agent, such as dexamethasone, a 5-HT3 RA, or a dopamine RA, such as metoclopramide, may be considered for prophylaxis in patients receiving chemotherapy of low emetic risk No antiemetic should be routinely administered before chemotherapy to patients without a history of nausea and vomiting receiving minimally emetogenic chemotherapy No antiemetic should be administered for prevention of delayed nausea and vomiting induced by low or minimally emetogenic chemotherapy If a patient experiences acute or delayed nausea or vomiting after low or minimally emetogenic chemotherapy, it is advised that, with subsequent chemotherapy treatments, the regimen for the next higher emetic level be given"
},
{
	"page":"ENAS5268_2.7.0.0",
	"text":"2.7.0.0 Breakthrough ChT-‍induced & refrac. emesis Antiemetics are most effective when used prophylactically and maximally effective agents should be used first-‍line rather than following failure However, breakthrough chemotherapy-‍induced emesis, defined as emesis and/‍or nausea occurring on the day of chemotherapy despite guideline recommended prophylaxis, remains an unsolved problem The use of an antiemetic with a different mechanism of action to that of the antiemetic(s) used for prophylaxis is recommended The available evidence for breakthrough nausea and vomiting suggests the use of olanzapine 10 mg orally daily for 3 days, which was more effective than metoclopramide Mild-to-moderate sedation, especially in elderly patients, is a potential problem For refractory emesis, defined as emesis in the previous cycle of chemotherapy, but without emesis before the subsequent cycle of chemotherapy, switching to a different 5-HT3 RA or adding other agents, such as dopamine RA or benzodiazepines, may be useful Metopimazine improved the efficacy of ondansetron with/without methylprednisolone Activity of NK1 receptor antagonists has been reported in cases in which dexamethasone and a serotonin receptor antagonist alone did not provide complete protection An antiemetic with a different mechanism of action to that of agents used in the previous cycle of chemotherapy is recommended"
},
{
	"page":"ENAS5268_2.8.0.0",
	"text":"2.8.0.0 Prev. of anticipatory nausea and vomiting Anticipatory nausea is believed to be a learned response to chemotherapy A history of poor chemotherapy-‍induced nausea or vomiting control, past experience with nausea and vomiting due to various causes (e.g. due to motion sickness) and anxiety can increase the risk of anticipatory nausea and vomiting Anticipatory nausea and vomiting is difficult to control by pharmacological treatment and the best approach is to prevent it by achieving the best possible control of acute and delayed nausea and vomiting Benzodiazepines are recommended to reduce the occurrence of anticipatory nausea and vomiting Behavioural therapies, in particular progressive muscle relaxation training, systematic desensitisation and hypnosis, may also be used to treat anticipatory nausea and vomiting"
},
{
	"page":"ENAS5268_2.9.0.0",
	"text":"2.9.0.0 Prevention by high-‍dose chemotherapy In patients treated with high-‍dose chemotherapy with stem cell transplantation (SCT), nausea and vomiting has several contributing causes, including the use of prophylactic antibiotics and opioids prescribed for concurrent mucositis management and the use of total body irradiation (TBI) The natural history of chemotherapy-‍induced nausea and vomiting in these patients is unknown, but most have experienced the effects with prior chemotherapy or irradiation In patients receiving ondansetron and dexamethasone prior to high-‍dose cyclophosphamide and SCT, the addition of aprepitant significantly reduced emesis, without increasing toxicity or the use of rescue medication In patients with multiple myeloma treated with melphalan and autologous SCT, aprepitant added to granisetron plus dexamethasone significantly increased the complete response rate and the rate of absence of major nausea and emesis on days 1–5 days after chemotherapy administration In conclusion, for patients receiving high-‍dose chemotherapy for SCT, a combination of a 5-HT3 RA with dexamethasone and aprepitant (125 mg orally on day 1 and 80 mg on days 2 to 4) is recommended before chemotherapy"
},
{
	"page":"ENAS5268_3.1.0.0",
	"text":"3.0.0.0 Prevention of RINV 3.1.0.0 Overview Radiotherapy-induced nausea and vomiting (RINV) is under-‍treated Emetic risk is based on the site of radiation and is divided into four levels: high, moderate, low and minimal, as shown in the table here In observational studies, irradiated site (upper abdomen), field size > 400 cm2 and concomitant chemotherapy were independent risk factors for RINV development Previous chemotherapy treatment is the only patient-related risk factor identified"
},
{
	"page":"ENAS5268_3.2.0.0",
	"text":"3.2.0.0 Radiotherapy emetic risk levels EMETIC RISK LEVEL: High AREA OF TREATMENT Total body irradiation ANTIEMETIC GUIDELINE Prophylaxis with a 5-HT3 RA + DEX MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS High/‍High (for the addition of DEX: Moderate/‍High) ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION II/B (for the addition of DEX: III/C) EMETIC RISK LEVEL: Moderate AREA OF TREATMENT Upper abdomen, craniospinal ANTIEMETIC GUIDELINE Prophylaxis with a 5-HT3-RA + optional DEX MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS High/‍High (for the addition of DEX: Moderate/‍High) ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION II/A (for the addition of DEX: II/B) EMETIC RISK LEVEL: Low AREA OF TREATMENT Cranium ANTIEMETIC GUIDELINE Prophylaxis or rescue with DEX MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS Low/‍High ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION IV/D EMETIC RISK LEVEL: Low AREA OF TREATMENT Head & neck, thorax region, pelvis ANTIEMETIC GUIDELINE Prophylaxis or rescue with DEX, a dopamine RA, or a 5-HT3 RA MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS Low/‍High ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION IV/D EMETIC RISK LEVEL: Minimal AREA OF TREATMENT Extremities, breast ANTIEMETIC GUIDELINE Rescue with DEX, a dopamine receptor antagonist, or a 5-HT3 RA MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS Low/‍High ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION IV/D EMETIC RISK LEVEL: Concomitant CRT AREA OF TREATMENT and ANTIEMETIC GUIDELINE In patients undergoing concomitant CRT the antiemetic prophylaxis should be according to the guidelines for CINV for the used chemotherapy. However, in case the emetic risk of RT is higher than that of the concomitant ChT, then the risk level of RT has to be chosen to tailor the antiemetic treatment. MASCC LEVEL OF SCIENTIFIC CONFIDENCE / LEVEL OF CONSENSUS Low/‍High ESMO LEVEL OF EVIDENCE / GRADE OF RECOMMENDATION IV/D 5-HT, 5-hydroxytryptamine; CINV, chemotherapy-induced nausea and vomiting; CRT, chemoradiotherapy; ChT, chemotherapy; DEX, dexamethasone; ESMO, European Society for Medical Oncology; MASCC, Multinational Association of Supportive Care in Cancer; RA, receptor agonist; RT, radiotherapy"
},
{
	"page":"ENAS5268_3.3.0.0",
	"text":"3.3.0.0 Risk classification The risk classification in the current guidelines differs from that in the 2010 guidelines as follows Total nodal irradiation has been removed as it is no longer in use Half body irradiation and upper body irradiation have been removed from the moderate risk category, as the risk of RINV is associated specifically with irradiation of the upper abdomen Craniospinal irradiation has been reclassified from low risk to moderate risk, based on data for large vertebral irradiation In the low risk category, ‘lower thorax’ has been replaced by ‘thorax’, based on the lack of distinction between the upper and lower regions in a study assessing RINV in patients receiving thorax radiotherapy"
},
{
	"page":"ENAS5268_3.4.0.0",
	"text":"3.4.0.0 Antiemetic treatment options No randomised, controlled antiemetic studies in RINV have been published since the 2010 guidelines A systematic review and meta-‍analysis of nine studies concluded that 5-HT3 RAs are superior to placebo or dopamine RAs in the prevention of emesis during radiotherapy but the evidence is less concrete for the control of nausea Thus, this analysis does not change existing guidelines recommendations A systematic review of 25 studies found no correlation between the duration of 5-HT3 RA prophylaxis and response rates, mainly due to the heterogeneity of the studies The updated recommendations are summarised in the table here The previous recommendation for the low emetic risk level (cranium, head & neck, thorax region and pelvis), which included prophylaxis or rescue with a 5-HT3 RA, has been changed to also include dexamethasone or a dopamine RA In clinical practice, the antiemetic treatment of choice in cranial irradiation is a corticosteroid (due to the oedema) and this was therefore included in the guideline For minimal risk, the recommendation is not restricted to a dopamine RA or a 5-HT3 RA but also includes dexamethasone"
},
{
	"page":"ENAS5268_3.5.0.0",
	"text":"3.5.0.0 Concurrent chemoradiotherapy For chemoradiotherapy (CRT), prescription of antiemetics according to the emetic risk of the chemotherapy is recommended, unless the risk of RINV is considered to be higher In patients receiving weekly cisplatin and 5 weeks of fractionated radiotherapy for cervical cancer, the addition of fosaprepitant to palonosetron and dexamethasone significantly reduced the risk of emesis Further studies in concurrent CRT are warranted"
},
{
	"page":"ENAS5268_4.0.0.0",
	"text":"4.0.0.0 Prevention of acute CINV in children Paediatric studies of antiemetic management present many limitations, including the use of adult-‍derived emetogenicity classification, evaluation of acute chemotherapy-‍induced nausea and vomiting only, varying definitions of complete control and the lack of use of a validated paediatric nausea assessment instrument The addition of aprepitant to ondansetron plus dexamethasone significantly improved the complete response rate in children receiving highly emetogenic chemotherapy, although in one trial uncertainty regarding the use of dexamethasone in each arm complicated interpretation of the results The recommendations for antiemetic prophylaxis in children receiving highly emetogenic chemotherapy are 5-HT3 RA (granisetron, ondansetron, tropisetron or palonosetron) plus dexamethasone plus aprepitant 5-HT3 RA plus aprepitant, in children unable to receive dexamethasone, due to prohibition by oncology study protocols 5-HT3 RA plus dexamethasone, when aprepitant administration is not feasible or desirable (IV fosaprepitant cannot be routinely recommended as paediatric experience is scant) Children receiving moderately emetogenic chemotherapy should receive antiemetic prophylaxis with a 5-HT3 RA plus dexamethasone Children receiving chemotherapy of low emetogenicity should receive no antiemetic prophylaxis"
},
{
	"page":"ENAS5268_5.1.0.0",
	"text":"5.0.0.0 ANTIEMETICS IN ADVANCED CANCER 5.1.0.0 Overview The causes of nausea and vomiting in advanced cancer can be multifactorial, including elevated intracranial pressure due to brain tumours, cerebral metastases or meningeal carcinomatosis, biochemical syndromes, vestibular dysfunction and gastric stasis-‍related factors Careful assessment, including a detailed history, physical examination and investigations for reversible causes, is paramount Approximately half of cases with a reversible cause are drug-‍related, mostly opioid induced The therapeutic approaches are empirical, starting with one drug and if unsuccessful adding or rotating to another, and aetiological, management tailored to the suspected cause and/‍or likely receptors involved Studies of antiemetic treatment are scarce and of poor quality Clinicians appear to favour metoclopramide as first-‍line therapy, on the basis of small randomised trials, with haloperidol as second-‍line therapy, followed by levomepromazine and olanzapine There is no evidence that combining antiemetics improves responses over monotherapy In conclusion, the antiemetic treatment of choice in advanced cancer is metoclopramide"
},
{
	"page":"ENAS5268_5.2.0.0",
	"text":"5.2.0.0 Nausea & vomiting in malignant bowel obs. Patients with nausea and vomiting due to malignant bowel obstruction unfit for surgery can be managed medically through two pharmacological approaches Anti-‍secretory drugs like anticholinergics (hyoscine hydrobromide, hyoscine butylbromide, glycopyrrolate) and/‍or somatostatin analogues, such as octreotide, with/without glucocorticoids Antiemetics alone or combined with anti-‍secretory drugs Few studies have assessed efficacy, although octreotide has been shown to reduce episodes of nausea and/‍or vomiting In conclusion, the drug recommended in bowel obstruction is octreotide, dosed around the clock, and given alongside a conventional antiemetic (with the committee recommending haloperidol) If octreotide plus an antiemetic is suboptimal the use of anticholinergic anti-‍secretory agents (e.g. scopolamine butylbromide, glycopyrronium bromide) and/‍or corticosteroids is recommended as either an adjunct or as an alternative intervention Metoclopramide should be used with caution in partial bowel obstruction and should not be used in complete bowel obstruction"
},
{
	"page":"ENAS5268_5.3.0.0",
	"text":"5.3.0.0 Opioid-induced nausea and vomiting Nausea and vomiting are commonly observed with opioid analgesics and may be an initiation side-‍effect, with tolerance after 5–7 days of therapy, or chronic No recommendation can be made about specific antiemetics in opioid-‍induced nausea and vomiting, although various antiemetics may help Opioid rotation and route switching may be effective approaches There are no data to support antiemetic prophylaxis in this situation ACUTE CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: SUMMARY EMETIC RISK GROUP ANTIEMETICS High Non-AC 5-HT3 + DEX + NK1 High AC 5-HT3 + DEX + NK1 Carboplatin 5-HT3 + DEX + NK1 Moderate (other than carboplatin) 5-HT3 + DEX Low 5-HT3 or DEX or DOP Minimal No routine prophylaxis 5-HT3, serotonin3 receptor antagonist; DEX, dexamethasone; NK1, neurokinin1 receptor antagonist such as aprepitant or fosaprepitant or rolapitant or NEPA (combination of netupitant and palonosetron); DOP, dopamine receptor antagonist NOTE: If the NK1 receptor antagonist is not available for AC chemotherapy, palonosetron is the preferred 5-HT3 receptor antagonist. DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: SUMMARY EMETIC RISK GROUP ANTIEMETICS High Non-AC DEX or (if APR 125 mg for acute: (MCP + DEX) or (APR + DEX)) High AC None or (if APR 125 mg for acute: DEX or APR) Carboplatin None or (if APR 125 mg for acute: APR) Oxaliplatin, or anthracycline, or cyclophosphamide DEX can be considered Moderate (other) No routine prophylaxis Low and Minimal No routine prophylaxis DEX, dexamethasone; MCP, metoclopramide; APR, aprepitant"
},
{
	"page":"ENAS5268_6.1.1.0",
	"text":"6.0.0.0 Summary of recommendations 6.1.0.0 Prevention of CINV 6.1.1.0 Levels of emetogenicity A four-‍level classification of IV chemotherapy agents has been accepted by registration authorities and groups producing recommendations on antiemetics: high (emetic risk > 90%), moderate (30–90%), low (10–30%) and minimal (< 10%) The following new emetogenic agents were identified since the 2010 guidelines Highly emetogenic agents: none, although the combined AC regimen for breast cancer is recommended for reclassification as a special case within this category, because delayed-‍phase treatment is different from cisplatin regimens Moderately emetogenic agents: seven (IV: temozolomide, trabectedin, romidepsin, thiotepa; Oral: bosutinib, crizotinib, ceritinib) Low emetogenic potential: 26 (IV: aflibercept, belinostat, blinatumomab, brentuximab, cabazitaxel, carfilzomib, eribulin, ipilimumab, nab-‍paclitaxel, pegylated liposomal doxorubicin, pertuzumab, trastuzumab-emtansine, vinflunine; Oral: afatinib, axatinib, dabrafenib, dasatinib, ibrutinib, idelalisib, nilotinib, olaparib, pazopanib, ponatinib, regorafenib, vandetanib, vorinostat) Minimally emetogenic: eight (IV: nivolumab, ofatumumab, pembrolizumab, pixantrone; Oral: pomalidomide, ruxolitinib, vemurafenib, vismodegib)"
},
{
	"page":"ENAS5268_6.1.2.1",
	"text":"6.1.2.0 Prevention by highly emetogenic ChT 6.1.2.1 Overview The 2010 guideline recommended a three-‍drug regimen including single doses of a 5-HT3 RA, dexamethasone and aprepitant given before chemotherapy to prevent acute nausea and vomiting following chemotherapy of high emetic risk and dexamethasone plus aprepitant or aprepitant alone to prevent delayed nausea and vomiting in cisplatin-‍treated / and AC-‍treated patients, respectively. Since then, new treatments have become available The NK1 RAs, netupitant and rolapitant, have been approved by the United States FDA (netupitant as NEPA combined with palonosetron and rolapitant) and the EMA (netupitant as NEPA combined with palonosetron) An IV formulation of aprepitant, fosaprepitant"
},
{
	"page":"ENAS5268_6.1.2.2",
	"text":"6.1.2.2 Cisplatin-‍treated patients The addition of an NK1 RA led to statistically and clinically significant improvements in response to anti-‍emetic treatment on day 1, days 2–5 and days 1–5 Foseprepitant (150 mg single dose) was as effective as the 3-day oral regimen of aprepitant, the combination of netupitant and palonosetron was superior to palonosetron alone and the addition of rolapitant significantly improved the effect of granisetron plus dexamethasone Therefore, for the prevention of non-‍AC highly emetogenic chemotherapy, a three-‍drug regimen including single doses of a 5-HT3 RA, dexamethasone, and an NK1 RA (aprepitant, fosaprepitant, netupitant or rolapitant), given before chemotherapy is recommended, with dexamethasone on days 2 to 4 to prevent delayed nausea and vomiting In patients receiving non-‍AC highly emetogenic chemotherapy treated with a combination of an NK1 RA, a 5-HT3 RA, and dexamethasone to prevent acute nausea and vomiting, dexamethasone on days 2 to 4 is suggested to prevent delayed nausea and vomiting For delayed nausea and vomiting, dexamethasone plus aprepitant or metoclopramide should be used in patients receiving aprepitant on day 1"
},
{
	"page":"ENAS5268_6.1.2.3",
	"text":"6.1.2.3 AC-‍treated female pts. with breast cancer Addition of netupitant to dexamethasone and palonosetron significantly increased the complete response on day 1 and days 1–5 and reduced the impact of nausea and vomiting on daily living Addition of rolapitant to granisetron and dexamethasone significantly improved complete response on days 1–5 and 2–5 The improvement in the delayed and overall phases is clinically relevant because of the potential positive impact on the complete response rate in subsequent chemotherapy cycles Therefore, in women with breast cancer receiving AC chemotherapy, a three-‍drug regimen including single doses of a 5-HT3 RA, dexamethasone and an NK1 RA (aprepitant, fosaprepitant, netupitant or rolapitant), given before chemotherapy is recommended In women with breast cancer treated with a combination of a 5-HT3 RA, dexamethasone and an NK1 RA to prevent acute nausea and vomiting, aprepitant or dexamethasone should be used on days 2 and 3 but not if fosaprepitant, netupitant or rolapitant has been used in day 1 If an NK1 receptor antagonist is not available for the prophylaxis of nausea and vomiting induced by AC chemotherapy, palonosetron is the preferred 5-HT3 RA"
},
{
	"page":"ENAS5268_6.1.2.4",
	"text":"6.1.2.4 Other highly emetogenic ChT These agents include mechlorethamine, streptozocin, cyclophosphamide > 1500 mg/m2, carmustine and dacarbazine Adding an NK1 RA to the combination of a 5-HT3 RA and dexamethasone for all non-‍cisplatin and non-‍AC highly emetogenic chemotherapy is recommended"
},
{
	"page":"ENAS5268_6.1.3.1",
	"text":"6.1.3.0 Dose, schedule, route & safety of antiemetics 6.1.3.1 Overview Suggested doses, schedules and routes of administration of the 5-HT3 RAs, the NK1 RAs and dexamethasone are given in the guidelines Electrocardiographic changes, particularly QTc prolongation, are a class effect of 5-HT3 RAs, with palonosetron having the lowest risk IV dolasetron and IV ondansetron (32 mg) were withdrawn due to cardiac adverse events A transdermal formulation of granisetron was non-‍inferior to 3–5 days of daily oral granisetron and a patch providing 3.1 mg granisetron/‍24 hours for up to 7 days is available Non-‍inferiority of oral palonosetron 0.5 mg vs IV 0.25 mg has been confirmed with cisplatin-‍based chemotherapy or moderate emetogenic chemotherapy A single 165 mg oral dose of aprepitant has received EMA (but not FDA) approval, although no clinical studies have been conducted Due to the risk of neurological effects, the EMA recommends that metoclopramide should not be used in children below 1 year of age and that the maximum dose for adults should be 30 mg/‍day (e.g. 10 mg x 3 orally) for no more than 5 days The authors of this guideline believe that 10 mg of metoclopramide is not superior to placebo in the effect against chemotherapy-‍induced nausea and vomiting and that higher doses are tolerable, when given for 2–3 days"
},
{
	"page":"ENAS5268_6.1.3.2",
	"text":"6.1.3.2 Olanzapine High complete response rates and high protection rates against nausea in patients receiving cisplatin-‍based or AC chemotherapy have been reported for olanzapine combined with a three-‍drug combination of a 5-HT3 RA, dexamethasone and the NK1 RA aprepitant Olanzapine appears to be superior to (fos)aprepitant in the prophylaxis of delayed nausea and equal to (fos)aprepitant in the prevention of acute symptoms Combination with a 5-HT3 RA plus dexamethasone can be considered, particularly when nausea is an issue, but patient sedation may be a concern with the 10 mg dose"
},
{
	"page":"ENAS5268_6.1.4.1",
	"text":"6.1.4.0 Prevention by MEC 6.1.4.1 Overview Previous MASCC/‍ESMO guidelines recommended palonosetron plus dexamethasone for the prophylaxis of acute nausea and vomiting For MEC associated with a significant incidence of delayed nausea and vomiting, antiemetic prophylaxis, preferably with multiday oral dexamethasone, for delayed emesis was recommended The prophylaxis of MEC-‍induced acute nausea and vomiting For the prevention of acute emesis in MEC-‍treated patients, a 5-HT3 RA plus dexamethasone is recommended An advantage for palonosetron compared with other 5-HT3 RAs, when both are combined with dexamethasone, has not been conclusively demonstrated The prophylaxis of MEC-‍induced delayed nausea and vomiting Some patients may have reduced nausea or vomiting with the addition of dexamethasone beyond 24 hours No new data allow the identification of patients at sufficiently high risk of delayed emesis to warrant prophylaxis For MEC agents other than carboplatin (see here), it can be concluded that in patients receiving MEC with a known potential for delayed emesis (e.g. oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered No routine prophylaxis for delayed emesis can be recommended for all other patients receiving MEC Which MEC should receive prophylaxis including an NK1 RA? Addition of an NK1 RA significantly improved antiemetic prophylaxis with 5-HT3 RA in AC and non-‍AC MEC-‍treated patients Not all MEC-‍treated patients have a sufficiently high risk of emesis to warrant prophylactic therapy including an NK1 RA from cycle 1 Addition of fosaprepitant (150 mg IV) to ondansetron plus dexamethasone significantly increased the complete response on days 1–5 and 2–5, but not day 1, compared with ondansetron plus dexamethasone in patients receiving non-‍AC MEC"
},
{
	"page":"ENAS5268_6.1.4.2",
	"text":"6.1.4.2 Carboplatin In carboplatin-‍treated patients adding an NK1 RA to a 5-HT3 RA and dexamethasone increased the complete response by approximately 10–15% Adding aprepitant to 5-HT3 RA plus dexamethasone improved nausea and vomiting in gynaecological and non-‍small cell lung cancers, but not all results were significant In conclusion, a combination of an NK1 RA, dexamethasone and a 5-HT3 RA is recommended to prevent carboplatin-‍induced acute nausea and vomiting Where fosaprepitant, netupitant or rolapitant is given on day 1, no antiemetic prophylaxis for delayed emesis is required Where aprepitant is given on day 1, aprepitant on days 2 and 3 is recommended"
},
{
	"page":"ENAS5268_6.1.4.3",
	"text":"6.1.4.3 Oxaliplatin Two large randomised trials came to conflicting conclusions about the role of NK1 RA (casopitant or aprepitant) in managing oxaliplatin-‍based chemotherapy-‍associated nausea and vomiting In view of these discordant results, no recommendation can be made about combining an NK1 RA with dexamethasone and a 5-HT3 RA for the prophylaxis of oxaliplatin-‍induced emesis"
},
{
	"page":"ENAS5268_6.1.5.0",
	"text":"6.1.5.0 Prev. by multiple-‍day cisplatin ChT Only a few studies have been carried out with multi-‍day chemotherapy studies including drugs such as dactinomycin, dacarbazine, ifosfamide and cisplatin In patients with germ cell tumours, the IV combination of a 5-HT3 RA plus dexamethasone was superior to IV high-‍dose metoclopramide plus dexamethasone, alizapride plus dexamethasone and to a 5-HT3 RA alone in protecting against vomiting during cisplatin administration Addition of aprepitant to a 5-HT3 RA plus dexamethasone significantly improved response rate compared with placebo, was preferred by patients and was not associated with increased toxicity Therefore, 5-HT3 RA plus dexamethasone plus aprepitant is recommended for the prevention of acute nausea and vomiting and dexamethasone for delayed nausea and vomiting in patients receiving multiple-‍day cisplatin for metastatic germ cell tumours"
},
{
	"page":"ENAS5268_6.1.6.0",
	"text":"6.1.6.0 Prev. by ChT with low & min. emetogenic pot. No guidelines recommend routine antiemetic prophylaxis against delayed emesis for low emetogenic chemotherapy A single antiemetic agent, such as dexamethasone, a 5-HT3 RA, or a dopamine RA, such as metoclopramide, may be considered for prophylaxis in patients receiving chemotherapy of low emetic risk No antiemetic should be routinely administered before chemotherapy to patients without a history of nausea and vomiting receiving minimally emetogenic chemotherapy No antiemetic should be administered for prevention of delayed nausea and vomiting induced by low or minimally emetogenic chemotherapy If a patient experiences acute or delayed nausea or vomiting after low or minimally emetogenic chemotherapy, it is advised that, with subsequent chemotherapy treatments, the regimen for the next higher emetic level be given"
},
{
	"page":"ENAS5268_6.1.7.0",
	"text":"6.1.7.0 Breakthrough ChT-‍induced & refrac. emesis Antiemetics are most effective when used prophylactically and maximally effective agents should be used first-‍line rather than following failure, although breakthrough chemotherapy-‍induced emesis remains an unsolved problem The use of an antiemetic with a different mechanism of action to that of the antiemetic(s) used for prophylaxis is recommended Olanzapine 10 mg orally daily for 3 days is recommended, although mild-‍to-‍ moderate sedation, especially in elderly patients, is a potential problem For refractory emesis, switching to a different 5-HT3 RA or adding other agents, such as dopamine RA or benzodiazepines, may be useful Metopimazine improved the efficacy of ondansetron with/without methylprednisolone Activity of NK1 receptor antagonists has been reported in cases in which dexamethasone and a serotonin receptor antagonist alone did not provide complete protection An antiemetic with a different mechanism of action to that of agents used in the previous cycle of chemotherapy is recommended"
},
{
	"page":"ENAS5268_6.1.8.0",
	"text":"6.1.8.0 Prev. of anticipatory nausea and vomiting A history of poor chemotherapy-‍induced nausea and vomiting control is among the risks for anticipatory nausea and vomiting Anticipatory nausea and vomiting is difficult to control by pharmacological treatment and the best approach is to prevent it by achieving the best possible control of acute and delayed nausea and vomiting Benzodiazepines are recommended to reduce the occurrence Behavioural therapies, in particular progressive muscle relaxation training, systematic desensitisation and hypnosis, may also be used as treatment"
},
{
	"page":"ENAS5268_6.1.9.0",
	"text":"6.1.9.0 Prevention by high-‍dose chemotherapy In patients treated with high-‍dose chemotherapy with SCT, causes of nausea and vomiting include the use of prophylactic antibiotics and opioids prescribed for concurrent mucositis management and the use of TBI Most patients have experienced nausea and vomiting with prior chemotherapy or irradiation Addition of aprepitant to ondansetron/dexamethasone or granisetron/‍ dexamethasone reduced symptoms in patients treated with high-‍dose cyclophosphamide or melphalan and SCT In conclusion, for patients receiving high-‍dose chemotherapy for SCT, a combination of a 5-HT3 RA with dexamethasone and aprepitant (125 mg orally on day 1 and 80 mg on days 2 to 4) is recommended before chemotherapy"
},
{
	"page":"ENAS5268_6.2.1.0",
	"text":"6.2.0.0 Prevention of RINV 6.2.1.0 Overview Emetic risk is based on the site of radiation and is divided into four levels: high, moderate, low and minimal In observational studies, irradiated site (upper abdomen), field size > 400 cm2 and concomitant chemotherapy were independent risk factors Previous chemotherapy treatment is the only patient-related risk factor identified"
},
{
	"page":"ENAS5268_6.2.2.0",
	"text":"6.2.2.0 Risk classification The risk classification in the current guidelines differs from that in the 2010 guidelines as follows Total nodal irradiation has been removed as it is no longer in use Half body irradiation and upper body irradiation have been removed from the moderate risk category as the risk of RINV is associated specifically with irradiation of the upper abdomen Craniospinal irradiation has been reclassified from low risk to moderate risk In the low risk category, ‘lower thorax’ has been replaced by ‘thorax’"
},
{
	"page":"ENAS5268_6.2.3.0",
	"text":"6.2.3.0 Antiemetic treatment options A systematic review and meta-‍analysis concluded that 5-HT3 RAs are superior to placebo or dopamine RAs in the prevention of emesis during radiotherapy but the evidence is less concrete for the control of nausea and this analysis does not change existing guidelines recommendations A systematic review found no correlation between the duration of 5-HT3 RA prophylaxis and response rates, mainly due to the heterogeneity of the studies Updated recommendations are given in the guidelines The previous recommendation for the low emetic risk level (cranium, head & neck, thorax region and pelvis), which included prophylaxis or rescue with a 5-HT3 RA, has been changed to also include dexamethasone or a dopamine RA In clinical practice, the antiemetic treatment of choice in cranial irradiation is a corticosteroid (due to the oedema) and this was therefore included in the guideline For minimal risk, the recommendation is not restricted to a dopamine RA or a 5-HT3 RA but also includes dexamethasone"
},
{
	"page":"ENAS5268_6.2.4.0",
	"text":"6.2.4.0 Concurrent chemoradiotherapy For CRT, prescription of antiemetics according to the emetic risk of the chemotherapy is recommended, unless the risk of RINV is considered to be higher In patients receiving weekly cisplatin and 5 weeks of fractionated radiotherapy for cervical cancer, the addition of fosaprepitant to palonosetron and dexamethasone significantly reduced the risk of emesis"
},
{
	"page":"ENAS5268_6.3.0.0",
	"text":"6.3.0.0 Prevention of acute CINV in children The addition of aprepitant to ondansetron plus dexamethasone significantly improved the complete response rate in children receiving highly emetogenic chemotherapy, although in one trial uncertainty regarding the use of dexamethasone in each arm complicated interpretation of the results The recommendations for antiemetic prophylaxis in children receiving highly emetogenic chemotherapy are 5-HT3 RA (granisetron, ondansetron, tropisetron or palonosetron) plus dexamethasone plus aprepitant 5-HT3 RA plus aprepitant, in children unable to receive dexamethasone, due to prohibition by oncology study protocols 5-HT3 RA plus dexamethasone, when aprepitant administration is not feasible or desirable (IV fosaprepitant cannot be routinely recommended as paediatric experience is scant) Children receiving moderately emetogenic chemotherapy should receive antiemetic prophylaxis with a 5-HT3 RA plus dexamethasone Children receiving chemotherapy of low emetogenicity should receive no antiemetic prophylaxis"
},
{
	"page":"ENAS5268_6.4.1.0",
	"text":"6.4.0.0 ANTIEMETICS IN ADVANCED CANCER 6.4.1.0 Overview The causes of nausea and vomiting in advanced cancer can be multifactorial and careful assessment, including a detailed history, physical examination and investigations for reversible causes, is paramount Approximately half of cases with a reversible cause are drug-‍related, mostly opioid induced The therapeutic approaches are either empirical, starting with one drug and if unsuccessful adding or rotating to another, or aetiological, management tailored to the suspected cause and/‍or likely receptors involved Clinicians appear to favour metoclopramide as first-‍line therapy, with haloperidol as second-‍line therapy, followed by levomepromazine and olanzapine There is no evidence that combining antiemetics improves responses over monotherapy In conclusion, the antiemetic treatment of choice in advanced cancer is metoclopramide"
},
{
	"page":"ENAS5268_6.4.2.0",
	"text":"6.4.2.0 Nausea & vomiting in malignant bowel obs. Patients with nausea and vomiting due to malignant bowel obstruction unfit for surgery can be managed medically through two pharmacological approaches Anti-‍secretory drugs like anticholinergics (hyoscine hydrobromide, hyoscine butylbromide, glycopyrrolate) and/‍or somatostatin analogues, such as octreotide, with/without glucocorticoids Antiemetics alone or combined with anti-‍secretory drugs Octreotide has been shown to reduce episodes of nausea and/‍or vomiting and is recommended in bowel obstruction, dosed around the clock, and given alongside a conventional antiemetic (with the committee recommending haloperidol) If octreotide plus an antiemetic is suboptimal the use of anticholinergic anti- secretory agents (e.g. scopolamine butylbromide, glycopyrronium bromide) and/‍or corticosteroids is recommended as either an adjunct or as an alternative intervention Metoclopramide should be used with caution in partial bowel obstruction and should not be used in complete bowel obstruction"
},
{
	"page":"ENAS5268_6.4.3.0",
	"text":"6.4.3.0 OPIOID-‍INDUCED NAUSEA AND VOMITING Nausea and vomiting are commonly observed with opioid analgesics No recommendation can be made about specific antiemetics in opioid-‍induced nausea and vomiting, although various antiemetics may help Opioid rotation and route switching may be effective approaches There are no data to support antiemetic prophylaxis in this situation"
},
{
	"page":"ENAS5268_7.0.0.0",
	"text":"5-FU 5-‍fluorouracil 5-HT 5-‍hydroxytryptamine Ab antibiotic ABC Airway, Breathing and Circulation ABLC amphotericin B lipid complex AC anthracycline/‍cyclophosphamide ACCP American College of Chest Physicians ACE angiotensin converting enzyme AChR acetylcholine receptor ACTH adrenocorticotropic hormone ADL activities of daily living ADR adverse drug reaction AE adverse event AFSOS Association Francophone pour les Soins Oncologiques de Support ALT antibiotic lock therapy ANA antinuclear antibody ANC absolute neutrophil count ANCA anti-neutrophil cytoplasmic antibody aPTT activated partial thromboplastin time ARB angiotensin receptor blocker ARDS acute respiratory distress syndrome ASA 5-‍acetyl salicylic acid ASCO American Society of Clinical Oncology AST antimicrobial susceptibility testing ATB antibiotic BAL bronchoalveolar lavage ATG anti-thymocyte globulin BB beta-‍blocking agents BCoG bacitracin/‍clotrimazole/‍gentamicin bid twice daily bid M/W/F twice daily Monday/Wednesday/Friday BNP brain natriuretic peptides BP blood pressure BSA body surface area BSI blood stream infection C Candida Ca calcium CFU colony-‍forming unit CHF congestive heart failure ChT chemotherapy CINV chemotherapy-induced nausea and vomiting CLL chronic lymphocytic leukaemia CMV cytomegalovirus CNS coagulase-‍negative Staphylococcus CPGs Clinical Practice Guidelines CrCl creatinine clearance CRBSI catheter-‍related blood stream infection CRI catheter-‍related infection CRP C-‍reactive protein CRS cytokine-release syndrome CRT chemoradiotherapy CT computed tomography CTCAE Common Terminology Criteria of Adverse Events CTLA4 cytotoxic T lymphocyte-associated protein 4 CV cardiovascular CVA cerebrovascular accident CVAD central venous access device CVC central venous catheter CYP cytochrome P450 DADS diffuse alveolar damage syndrome DDx differential diagnosis DEX dexamethasone DM diabetes mellitus DMSO dimethyl sulfoxide DRESS drug rash with eosinophilia and systemic symptoms DT deceleration time of the early peak flow DTTP differential time to positivity DVH dose volume histogram DVT deep vein thrombosis DW dextrose water E Enterococcus E/A ratio ratio of early peak flow velocity to atrial peak flow velocity ECG electrocardiogram ECHO echocardiography EDTA ethylenediaminetetraacetate EGFR epidermal growth factor receptor EMA European Medicines Agency EMG electromyography EORTC European Organisation for Research and Treatment of Cancer ESBL Enterococcus Staphylococci Extended spectrum ß-‍lactamase ESMO European Society for Medical Oncology ESR erythrocyte sedimentation rate FBC full blood count FDA Food and Drug Administration FN febrile neutropaenia FSH follicle-stimulating hormone FT4 free thyroxine GAD glutamic acid decarboxylase GBM glomerular basement membrane GBS Guillain-Barré syndrome G-CSF granulocyte-‍colony stimulating factor GI gastrointestinal GM-‍CSF granulocyte-‍macrophage colony-‍stimulating factor GN glomerulonephritis GNB Gram-‍negative bacillus Hb haemoglobin HER2 human epidermal growth factor 2 HIV human immunodeficiency virus HNC head and neck cancer HRT hormone replacement therapy HSCT haematopoietic stem cell transplantation HSR hypersensitivity reaction HSV herpes simplex virus ICPi immune checkpoint inhibitor ID infectious diseases Ig immunoglobulin IgE immunoglobulin E IGF1 insulin-like growth factor 1 IgG immunoglobulin G IM intramuscular IMRT intensity-‍modulated radiotherapy INR international normalised ratio IR infusion reaction irAE immune-related adverse event ISOO International Society of Oral Oncology IV intravenous IVIg intravenous immunoglobulin IVRT isovolumic relaxation time K potassium KGF-1 keratinocyte growth factor-1 LCI lung clearance index LDH lactate dehydrogenase LFT liver function test LH luteinising hormone LKM liver kidney microsomal LLN lower limit of normal LMWH low molecular weight heparin LVD left ventricular dysfunction LVEF left ventricular ejection fraction M/C/S microscopy, culture and susceptibility MASCC Multinational Association of Supportive Care in Cancer MDR multi-‍drug resistant MEC moderately emetogenic chemotherapy MHD maximum heart distance mIAS mTOR inhibitor-‍associated stomatitis MIC minimum inhibitory concentration MMF mycophenolate mofetil MoAb monoclonal antibody MRA magnetic resonance angiogram MRI magnetic resonance imaging MRSA methicillin-resistant S. aureus mTOR mechanistic target of rapamycin MUGA multiple gated acquisition MuSK muscle-specific kinase Mx management n/a not available NaCl sodium chloride NCCN National Comprehensive Cancer Network NCI-‍CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events NCS/EMG nerve conduction studies/electromyography NEG negative NK neurokinin NS normal saline NSAID non-‍steroidal anti-‍inflammatory drug NSCLC non-small-cell lung cancer NTCP normal tissue complication probability NYHA New York Heart Association od once daily ONS Oncology Nursing Society OS overall survival P pseudomonas PCR polymerase chain reaction PD-1 programmed death 1 PD-L1 programmed death ligand 1 PE pulmonary embolism PICC peripherally inserted central catheter PJP Pneumocystis jiroveci pneumonia POS positive PS performance status PTA polymyxin/tobramycin/amphotericin B PTV planning target volume QTc QT interval corrected for heart rate RA receptor agonist RINV radiotherapy-induced nausea and vomiting RT radiotherapy S Staphylococcus SC subcutaneous SCT stem cell transplantation SFNEP Société Francophone Nutrition Clinique et Métabolique SLA/LP soluble liver antigen/liver-pancreas antibody SMA smooth muscle autoantibody SOR Standards, Options and Recommendations methodology spp species SVC superior vena cava T3 triiodothyronine T4 thyroxine TB tuberculosis TBI total body irradiation TCLO transfer factor for carbon monoxide tds three times a day TEE trans-‍oesophageal echocardiogram TKI tyrosine kinase inhibitor TMP-‍SMZ trimethoprim–sulfamethoxazole TNFα tumour necrosis factor alpha TnI troponin tPA tissue plasminogen activator TPN total parenteral nutrition TPO thyroid peroxidase TSH thyroid-stimulating hormone U unit UEC urea, electrolytes, creatinine UFH unfractionated heparin ULN upper limit of normal UPCR urine protein to creatinine ratio US ultrasound VATS video-assisted thoracoscopic surgery VEGF vascular endothelial growth factor VEGFR vascular endothelial growth factor receptor VHNSS Vanderbilt Head and Neck Symptom Survey VitD vitamin D VKA vitamin K antagonist VTE venous thromboembolism WBC white blood cell WHO World Health Organization"
}
]